ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York
Renexxion will stream a presentation and hold one-to-one meetings as it advances naronapride toward global pivotal studies for gastroparesis.
- Renexxion, Inc. and Intrusion Inc. announced plans to participate in the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 14–16, 2026. Both companies will present their latest developments to investors during the three-day event.
- Renexxion management, including Chief Executive Officer Peter Milner and Chief Medical Officer Christian Flynn, will provide an update on their lead asset, naronapride. The drug aims to treat gastroparesis by restoring natural gastrointestinal signaling pathways.
- Intrusion's Chief Executive Officer Tony Scott and Chief Financial Officer Kimberly Pinson will present the company's "AI-powered" cyberattack prevention solutions at the conference. The executives will also host one-on-one meetings to discuss managed cybersecurity offerings.
- Scheduled for September 14–16, 2026, the conference serves as a platform for both firms to engage directly with the investment community. Representatives from each organization will be available throughout the event to address investor inquiries.
- These presentations highlight the companies' focus on addressing critical industry needs, ranging from clinical gastrointestinal treatments to cybersecurity defense. Both Renexxion and Intrusion aim to leverage this platform to communicate their long-term value propositions to global investors.
13 Articles
13 Articles
Intrusion Inc. Announces Participation in the H.C. Wainwright Annual Global Investment Conference
PLANO, TX / ACCESS Newswire / September 9, 2026 / Intrusion Inc. (NASDAQ:INTZ) ("Intrusion" or the "Company"), a provider of AI-powered cyberattack prevention, threat intelligence, and managed cybersecurity solutions, announced today that Tony Scott, CEO, and Kimberly Pinson, CFO, will…
Helus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New York
NEW YORK and TORONTO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today announced that…
Hastings Tribune
The Manila TimesImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York
SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that chief executive officer Kristin Yarema, Ph.D., will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference…
Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment ...
SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announces that it will participate in the H.C. Wainwright 28th Annual…
Coverage Details
Bias Distribution
- 63% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
